The Residual Tumor Autophagy Marker LC3B Serves as a Prognostic Marker in Local Advanced Breast Cancer after Neoadjuvant Chemotherapy
Authors:
- 15 December 2013
- journal article
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 19 (24) , 6853-6862
Abstract
This study sought to investigate the prognostic value of the autophagy marker microtubule-associated protein chain 3B (LC3B) in patients with residual tumors after neoadjuvant chemotherapy (NCT) for locally advanced breast cancer (LABC). The expression of LC3B in residual breast cancer cells was assessed by immunohistochemistry in surgical specimens from 229 patients diagnosed with histologically proven invasive breast cancer. All patients underwent NCT followed by mastectomy and were considered nonpathologic complete responders (non-pCR) after a pathologic evaluation. The prognostic value of various clinicopathologic factors was evaluated. The LC3B density was similar between the peripheral and central area of the tumors (P = 0.328) but was significantly lower in the extratumoral area (P < 0.001 and P < 0.001, respectively). Furthermore, LC3B density, which correlated with Beclin-1 expression, Ki-67 index, and breast cancer subtype, served as an independent prognostic factor for both relapse-free survival (RFS; P = 0.012) and overall survival (OS; P = 0.008); the prognostic value of LC3B was most significant in triple-negative patients. Using a combination of LC3B expression and the status of residual involved lymph nodes, the patients were classified into four groups with different risks of relapse and death (P < 0.001 for RFS and P = 0.003 for OS). LC3B can be used as a prognostic marker in patients with non-pCR after NCT for breast cancer, which highlights the importance of autophagy in the biologic behavior of chemoresistant cancer cells. Furthermore, evaluating and targeting autophagy in the neoadjuvant setting may help prevent disease relapse in patients with non-pCR.Keywords
This publication has 33 references indexed in Scilit:
- Beclin 1 and autophagy are required for the tumorigenicity of breast cancer stem-like/progenitor cellsOncogene, 2012
- Strategies for subtypes—dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011Annals of Oncology, 2011
- Ki-67 can be used for further classification of triple negative breast cancer into two subtypes with different response and prognosisBreast Cancer Research, 2011
- Methods in Mammalian Autophagy ResearchCell, 2010
- A risk score to predict disease-free survival in patients not achieving a pathological complete remission after preoperative chemotherapy for breast cancerAnnals of Oncology, 2009
- Basal-Like Breast Cancer Defined by Five Biomarkers Has Superior Prognostic Value than Triple-Negative PhenotypeClinical Cancer Research, 2008
- Autophagy fights disease through cellular self-digestionNature, 2008
- Prognostic markers in triple‐negative breast cancerCancer, 2006
- Autophagy promotes tumor cell survival and restricts necrosis, inflammation, and tumorigenesisCancer Cell, 2006
- The role of autophagy in cancer development and response to therapyNature Reviews Cancer, 2005